BridgeBio Pharma, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
BridgeBio Pharma issued 933.9M shares of Series A Cumulative Convertible Participating Preferred Stock to unspecified purchasers (Sixth Street Partners and HCR Equity Partners implied) at $1,000/share closing July 1, 2026. Preferred stock is convertible to 45M common shares, carries 7.00% annual dividend (escalating to 17% cap), senior liquidation preference, and Majority Vote class veto rights. Company must reserve 45M common shares, obtain stockholder approval for conversion, maintain Nasdaq listing, and comply with debt/dividend covenants.
Why this rating
~$934M capital raise (~13% of $7.3B market cap) is material but non-transformational. Preferred terms are founder-hostile; equity dilution is real if converted. No immediate business threat; moderate financing boost.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.